**Author details**

Carlos Melero Moreno1 \*, Marta Corral Blanco2 and Rocío Magdalena Díaz Campos2

1 Institute for Health Research (i+12), Hospital Universitario 12 de Octubre, Madrid, Spain

2 Pneumology Service, Hospital Universitario 12 de Octubre, Madrid, Spain

\*Address all correspondence to: cmelero@separ.es

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**187**

*Eosinophilic Granulomatosis with Polyangiitis: The Beginning of a New Era*

multiethnic population in 2000: A capture-recapture estimate. Arthritis and Rheumatism. 2004;**51**:92-99

[8] Sada KE, Amano K, Uehara R, Yamamura M, Arimura Y, Nakamura Y, et al. A nationwide survey on the epidemiology and clinical features of eosinophilic granulomatosis with polyangiitis (Churg-Strauss) in Japan. Modern Rheumatology.

[9] Furuta S, Iwamoto T, Nakajima H. Update on eosinophilic granulomatosis

[10] Thompson GE, Specks U. Update on the management of respiratory manifestations of the antineutrophil cytoplasmic antibodies-associated vasculitides. Clinics in Chest Medicine.

with polyangiitis. Allergology International. 2019; pii: S1323- 8930(19)30081-4. DOI: 10.1016/j. alit.2019.06.004. [Epub ahead of print]

2014;**24**:640-644

2019;**40**:573-582

ahead of print]

2011;**90**:19-27

[11] Matsumoto K, Suzuki K, Yoshimoto K, Seki N, Tsujimoto H, Chiba K, et al. Significant association between clinical characteristics and immune-phenotypes in patients with ANCA-associated vasculitis. Rheumatology. 2019. pii: kez327. DOI: 10.1093/rheumatology/kez327. [Epub

[12] Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, et al. EULAR/ERA-EDTA recommendations

[13] Guillevin L, Pagnoux C, Seror R, Mahr A, Mouthon L, Toumelin PL. The five-factor score revisited. Medicine.

[14] Cottin V, Bel E, Bottero P, Dalhoff K, Humbert M, Lazor R. Respiratory

for the management of ANCAassociated vasculitis. Annals of the Rheumatic Diseases. 2016;**75**:1583-1594

*DOI: http://dx.doi.org/10.5772/intechopen.89054*

[1] Fujimoto S, Watts RA, Kobayashi S, Suzuki K, Jayne DR, Scott DG, et al. Comparison of the epidemiology of anti-neutrophil cytoplasmic

antibody-associated vasculitis between Japan and the UK. Rheumatology.

[2] Gonzalez-Gay MA, Garcia-Porrua C, Guerrero J, Rodriguez-Ledo P, Llorca J. The epidemiology of the primary systemic vasculitides in Northwest Spain: Implications of the Chapel Hill consensus conference definitions. Arthritis and Rheumatism.

2011;**50**:1916-1920

**References**

2003;**49**:388-393

[3] Reinhold-Keller E, Herlyn K,

incidence of primary systemic

and Rheumatism. 2005;**53**:93-99

[4] Mohammad AJ, Jacobsson LT, Westman KW, Sturfelt G, Segelmark M.

Incidence and survival rates in

polyangiitis, Churg-Strauss

Wagner-Bastmeyer R, Gross WL. Stable

vasculitides over five years: Results from the German vasculitis register. Arthritis

Wegener's granulomatosis, microscopic

syndrome and polyarteritis nodosa. Rheumatology. 2009;**48**:1560-1565

[5] Watts RA, Lane SE, Bentham G, Scott DG. Epidemiology of systemic vasculitis: A ten-year study in the United Kingdom. Arthritis and Rheumatism; 2000;**43**:414-419

[6] Martin RM, Wilton LV, Mann RD. Prevalence of Churg-Strauss syndrome, vasculitis, eosinophilia and associated conditions: Retrospective analysis of 58 prescription-event monitoring cohort studies. Pharmacoepidemiology and

[7] Mahr A, Guillevin L, Poissonnet M, Ayme S. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban

Drug Safety. 1999;**8**:179-189

*Eosinophilic Granulomatosis with Polyangiitis: The Beginning of a New Era DOI: http://dx.doi.org/10.5772/intechopen.89054*
